These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 23356097)

  • 1. The ethics of postmarketing observational studies of drug safety under section 505(o)(3) of the Food, Drug, and Cosmetic Act.
    Evans BJ
    Am J Law Med; 2012; 38(4):577-606. PubMed ID: 23356097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional Incumbency.
    Herder M
    Milbank Q; 2019 Sep; 97(3):820-857. PubMed ID: 31407412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA's Unimproved Enforcement of Postmarketing Requirements and Commitments: Implications for Providers and Patients.
    Dauner DG; Dauner KN; Peterson ALH
    Res Social Adm Pharm; 2020 Jun; 16(6):844-847. PubMed ID: 31812502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
    Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.
    Kesselheim AS; Mello MM
    Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustainable access to data for postmarketing medical product safety surveillance under the amended HIPAA Privacy Rule.
    Evans BJ
    Health Matrix Clevel; 2014; 24():11-47. PubMed ID: 25112134
    [No Abstract]   [Full Text] [Related]  

  • 8. Public Figures, Professional Ethics, and the Media.
    Fowler DR
    AMA J Ethics; 2016 Aug; 18(8):839-42. PubMed ID: 27550569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National health information privacy: regulations under the Health Insurance Portability and Accountability Act.
    Gostin LO
    JAMA; 2001 Jun; 285(23):3015-21. PubMed ID: 11410101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
    Skydel JJ; Luxkaranayagam AT; Dhruva SS; Ross JS; Wallach JD
    JAMA Netw Open; 2019 May; 2(5):e193410. PubMed ID: 31074812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manufacturer's drug interaction and postmarketing adverse event data: what are appropriate uses?
    Kraft WK; Waldman SA
    Drug Saf; 2001; 24(9):637-43. PubMed ID: 11522118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
    Beninger P; Murray M
    Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical records and privacy: empirical effects of legislation.
    McCarthy DB; Shatin D; Drinkard CR; Kleinman JH; Gardner JS
    Health Serv Res; 1999 Apr; 34(1 Pt 2):417-25. PubMed ID: 10199685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using electronic health information for pharmacovigilance: the promise and the pitfalls.
    Rosati K
    J Health Life Sci Law; 2009 Jul; 2(4):171, 173-239. PubMed ID: 19673181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA Safety Reviews on Drugs, Biologics, and Vaccines: 2007-2013.
    Cope JU; Rosenthal GL; Weinel P; Odegaard A; Murphy DM
    Pediatrics; 2015 Dec; 136(6):1125-31. PubMed ID: 26598453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Perils of Parity: Should Citizen Science and Traditional Research Follow the Same Ethical and Privacy Principles?
    Evans BJ
    J Law Med Ethics; 2020 Mar; 48(1_suppl):74-81. PubMed ID: 32342738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public good, personal privacy: a citizens' deliberation about using medical information for pharmacoepidemiological research.
    Parkin L; Paul C
    J Epidemiol Community Health; 2011 Feb; 65(2):150-6. PubMed ID: 19948532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.